Point72 Asset Management
ALNY icon

Point72 Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Point72 Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,197
Closed -$2.74M – 3884
2025
Q3 		$2.83M Sell
6,197
-195,199
-97% -$79.5M ﹤0.01% 1304
2025
Q2 		$65.7M Sell
201,396
-99,239
-33% -$27.5M 0.13% 202
2025
Q1 		$81.2M Buy
+300,635
New +$77.3M 0.19% 124
2024
Q2 		– Sell
-206,255
Closed -$30.8M – 1821
2024
Q1 		$30.8M Buy
206,255
+120,265
+140% +$20.1M 0.07% 316
2023
Q4 		$16.5M Buy
+85,990
New +$14.6M 0.04% 502
2022
Q4 		– Sell
-14,570
Closed -$2.92M – 1495
2022
Q3 		$2.92M Sell
14,570
-318,630
-96% -$60.8M 0.01% 845
2022
Q2 		$48.6M Buy
+333,200
New +$47.3M 0.21% 128
2021
Q4 		– Sell
-99,512
Closed -$18.8M – 1073
2021
Q3 		$18.8M Sell
99,512
-20,177
-17% -$3.78M 0.08% 324
2021
Q2 		$20.3M Sell
119,689
-320,248
-73% -$46.9M 0.09% 285
2021
Q1 		$62.1M Sell
439,937
-41,963
-9% -$6.31M 0.29% 81
2020
Q4 		$62.6M Buy
+481,900
New +$64.3M 0.31% 70
2019
Q3 		– Sell
-398,928
Closed -$28.9M – 1109
2019
Q2 		$28.9M Buy
+398,928
New +$30.6M 0.15% 176
2018
Q4 		– Sell
-885,312
Closed -$77.5M – 936
2018
Q3 		$77.5M Sell
885,312
-471,096
-35% -$47.4M 0.32% 81
2018
Q2 		$134M Buy
1,356,408
+448,362
+49% +$44.5M 0.53% 40
2018
Q1 		$108M Buy
908,046
+819,160
+922% +$106M 0.45% 45
2017
Q4 		$11.3M Buy
88,886
+3,886
+5% +$488K 0.05% 420
2017
Q3 		$9.99M Buy
85,000
+35,000
+70% +$2.99M 0.04% 397
2017
Q2 		$3.99M Buy
+50,000
New +$3.2M 0.02% 548
2014
Q4 		– Sell
-12,100
Closed -$945K – 652
2014
Q3 		$945K Buy
+12,100
New +$781K 0.01% 560

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management's ALNY Position: Q4 2025 in Review

Point72 Asset Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 6,197 shares — an estimated $2.74M sold.

Point72 Asset Management first reported a position in ALNY in Q3 2014 and held it in 19 quarters. The position peaked at $134M in Q2 2018. 848 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

  • Point72 Asset Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Point72 Asset Management sold 6,197 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $2.74M.
  • Point72 Asset Management first reported a position in Alnylam Pharmaceuticals in Q3 2014 and held it in 19 quarters.
  • Point72 Asset Management's Alnylam Pharmaceuticals position peaked at $134M in Q2 2018.
  • 848 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on Point72 Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.